# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
All of the Class A ordinary shares in the underwritten public offering and concurrent registered direct offering are being sold...
30-Day Option For Underwriters To Purchase Up To An Additional 15%
Jefferies analyst Kelly Shi maintains ProKidney (NASDAQ:PROK) with a Buy and lowers the price target from $15 to $6.